| Intrinsic Valuation of: SUNPHARMA | |||||||||||
| Free Cash Flow Average and Growth over past 5Y | Key Statistics | ||||||||||
| Year | FCF | FCF (FCF/Revenue) | |||||||||
| 2020 | - | - | EPS (FY) | 45 | Market Cap | ₹4,506B | |||||
| 2021 | - | - (-) | P/E Ratio | 41 | Total Asset | ₹921B | |||||
| 2022 | ₹75B | - (-) | Net Income | ₹109B | Total Debt | ₹25M | |||||
| 2023 | ₹29B | -61.6% (-65.9%) | EBITDA | ₹166B | Total Liab | ₹196B | |||||
| 2024 | ₹99B | 245.7% (213.2%) | Opr Margin | 24.18 | Debt/Equity | 0.00 | |||||
| 2025 | ₹119B | 20.2% (10.3%) | PreTax Margin | 23.73 | BV/Share | 226 | |||||
| 5Y Average FCF | ₹81B | 15.0% (52.5%) | |||||||||
| Overall Market Assumptions: | |||||||||||
| Assumptions: | P/E for No-Growth Company: | 7.0 | |||||||||
| Perpetual Growth Rate (g): | 2.48% | Historical US Bond Yield: | 4.40% | ||||||||
| Discount Rate (WACC): | 7.00% | Current US Bond Yield: | 3.48% | ||||||||
| Forcasting Future Free Cash Flow for next 6Y | Modified Benjamin Graham's Intrinsic Value | ||||||||||
| Year | FCF Projection (15.0%) | ||||||||||
| 2026 | ₹124B | MBG Intrinsic Value | ₹406 | ||||||||
| 2027 | ₹139B | ||||||||||
| 2028 | ₹153B | ||||||||||
| 2029 | ₹165B | ||||||||||
| 2030 | ₹173B | ||||||||||
| 2031 | ₹177B | ||||||||||
| Terminal Value | ₹4,021B | Net Worth/Share | ₹302 | ||||||||
| DCF Valuation | DCF Valuation "What If" Scenario Table | ||||||||||
| Enterprise Value | ₹3,410B | Growth Rate | |||||||||
| (+) Cash & Cash Equivalents | ₹103B | ₹1,464 | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | ||||
| (-) Total Debt | ₹25M | WACC | 6.5% | 1,376 | 1,495 | 1,644 | 1,834 | 2,088 | |||
| Equity Value | ₹3,512B | 7.1% | 1,224 | 1,314 | 1,424 | 1,559 | 1,732 | ||||
| Shares Outstanding | 2,399,334,970 | 7.8% | 1,104 | 1,175 | 1,258 | 1,360 | 1,485 | ||||
| 8.4% | 1,005 | 1,061 | 1,126 | 1,204 | 1,297 | ||||||
| DCF Intrinsic Value | ₹1,464 | 9.0% | 923 | 968 | 1,021 | 1,082 | 1,154 | ||||
| Analyzed by QuantJuice (2025) | |||||||||||